| INTRODUC TI ON
Vascular endothelial growth factor-tyrosine kinase inhibitors, including sunitinib and sorafenib, are clinically used for advanced ccRCC, and they are thought to exert therapeutic effects on ccRCC by antagonizing the VEGF receptor, leading to reduced angiogenesis.
1
Although VEGF-TKI treatment is considered to be superior to conventional immunotherapy, 2 resistance to therapy is commonly observed in most ccRCC patients treated with VEGF-TKI within 1 year after treatment. 2 Several molecular mechanisms for resistance are suggested such as the tumor immune escape mechanism, cancer stem cells, epithelial mesenchymal transition, and reactivation of angiogenesis. 1, [3] [4] [5] Among them, the tumor immune escape mechanism is considered to be one of the hallmarks of cancer because cancer cells need to escape from destruction by the immune system to survive.
6
Programmed death-ligand 1 is known to be expressed by both TIIC in the tumor microenvironment and tumor cells, and it engages PD-1 on T cells, triggering inhibitory signaling of the T-cell receptor, thereby blocking effector functions and reducing T cell killing capacity. 7 Clinical studies investigating the effects of PD-1/PD-L1
blockade have yielded promising results in patients with advanced melanoma and other cancers, including RCC. 8 As not all patients respond to PD-1/PD-L1 blockade therapy, it is important and necessary for treatment selection to predict the likelihood of response to therapy. Therefore, information from the tumor microenvironment is important because it represents an excellent opportunity for ccRCC patients to have access to new drugs and for clinicians to find prognostic and predictive immune biomarkers. However, the focus of analyses of PD-L1 in RCC is usually on its expression by tumor cells, 9- 11 and the significance of PD-L1 expression by TIIC is unclear.
10
Certain subsets of cancer patients respond poorly to targeted therapies, probably due to the regional heterogeneity of target molecules, and immunotherapy is no exception. Expression of PD-1 and PD-L1 might have more regional heterogeneity than other mutation alterations because the PD-1/PD-L1 axis is part of a dynamic immune reaction. Indeed, recent studies suggest that the value of PD-L1 immunohistochemistry as a predictive and prognostic marker is debatable because of frequent heterogeneity. 12, 13 Therefore, the regional heterogeneity of PD-1 and PD-L1 expression should be evaluated in detail in ccRCC tissues. To the best of our knowledge, however, there has been no report on the regional heterogeneity of PD-1 and PD-L1 expression on TIIC in the tumor microenvironment of ccRCC tissues. The present study was carried out to investigate the clinical relevance of PD-1 and PD-L1 expression by TIIC in the tumor microenvironment of ccRCC tissues, focusing on the heterogeneity of PD-1 and PD-L1 expression by TIIC, and its association with VEGF-TKI treatment.
| MATERIAL S AND ME THODS

| Clear cell RCC tissues without pretreatment
Total or partial nephrectomy specimens were obtained from 100 primary RCC patients without pretreatment from 1994 to 2014 at Keio University Hospital (Tokyo, Japan), and were used in the present study. This study was undertaken after approval by the Institutional separately. 19 The tumor periphery is the area around and adjacent to the tumor nest. All sections were reviewed at low magnification . Receiver operating characteristic curve analysis was undertaken to determine the area under the curve, and the optimal cut-off value was taken as the farthest point from the diagonal line of the curve. 4 Cases in which the PD-1-positive TIIC score, PD-L1-positive TIIC score, or PD-L1-positive tumor score was higher than the cut-off values were defined as high cases, and those with percentages lower than the cut-off values were defined as low cases. The log-rank test and Kaplan-Meier method were used for survival analyses. Differences among groups were regarded as significant when P values were less than 0.05. These analyses were carried out using IBM SPSS 24, Windows version (IBM, Armonk, NY, USA).
| RE SULTS
| Expression of PD-1 and PD-L1 in the tumor nest and tumor periphery of ccRCC without pretreatment, and its association with clinicopathological parameters
We investigated PD-1 and PD-L1 expression by TIIC at the tumor nest and tumor periphery. In low-grade ccRCC, no or very few 
PD-1-positive TIIC were observed at the tumor nest and tumor periphery (Fig. 1A-C, arrows) , whereas many TIIC were observed in high-grade ccRCC tissues ( Fig. 1D-F, arrows) . Staining of PD-1 on TIIC was observed in 43 ccRCC cases (43%) at the tumor nest, whereas it was observed in 44 cases (44%) at the tumor periphery.
Tumor cell expression of PD-1 was not observed. The mean PD-1-positive TIIC score at the tumor periphery was significantly higher than that at the tumor nest (8.2 vs 4.1) (P < 0.001). The correlation between PD-1 and PD-L1 expression in ccRCC and the clinicopathological parameters is summarized in Table 1 . Programmed death-1 expression both at the tumor nest and tumor periphery was associated with pathological tumor stage, distant metastasis, and histological grade (Table 1 ).
In many low-grade ccRCC, neither PD-L1-positive TIIC nor PD-L1-positive tumor cells were observed ( Fig. 1G-I ). High-grade ccRCC often had PD-L1-positive TIIC at both the tumor nest and tumor periphery ( Fig. 1J-L) . Programmed death ligand-1-positive TIIC were found in 24 ccRCC cases (24%) at the tumor nest and 31 cases (31%)
at the tumor periphery. The mean PD-L1-positive TIIC score at the tumor periphery was 2.7, and it was higher than that at the tumor nest (0.6) (P = 0.011). The PD-L1-positive TIIC score both at the tumor nest and tumor periphery was associated with pathological tumor stage and histological grade (Table 1) . Programmed death ligand-1-positive tumor cells were observed in 18% of ccRCC, and the mean PD-L1-positive tumor score was 3.1. The PD-L1-positive tumor score was only associated with histological grade, but not with primary tumor stage, or regional or distant metastasis (Table 1) .
| Prognostic significance of PD-1 and PD-L1 in patients with ccRCC without pretreatment
Receiver operating characteristic curve analysis was carried out to determine reasonable cut-off points for the PD-1-positive TIIC score, PD-L1-positive TIIC score, and PD-L1 tumor score (data now shown). Patients with ccRCC harboring a high PD-1-positive TIIC score at the tumor nest had significantly shorter progression-free and overall survival rates than those with tumors with a low PD-1-positive TIIC-positive score (P = 0.007 and P < 0.001) ( Fig. 2A,B) .
Similarly, a high PD-1-positive TIIC score at the tumor periphery was associated with poor progression-free survival (P = 0.006) (Fig. 2C) . No significant association was observed between the PD-1-positive TIIC score at the tumor periphery and overall survival (P = 0.228) (Fig. 2D) .
The PD-L1-positive TIIC score at the tumor nest was not associated with progression-free survival (P = 0.260) (Fig. 2E ), but patients with a high PD-L1-positive TIIC score at tumor nest had a significantly shorter overall survival than those with tumors harboring low PD-L1-positive TIIC score (P < 0.001) (Fig. 2F) . A high PD-L1-positive TIIC score at the tumor periphery was not associated with progression-free survival (P = 0.100) (Fig. 2G ), but it was associated with poor overall survival (P < 0.001) ( The objective response rate characterized by an experienced urologist (R.M.) according to RECIST was 5 patients (29%), all PR.
Standard disease was noted as the best response for 10 patients (59%). The remaining 2 patients (12%) had PD as the best response.
As shown in Fig. 3A -E, there was no significant association between the objective response and PD-1-positive TIIC score, PD-L1-positive TIIC score, or PD-L1-positive tumor score. In contrast, ccRCC tissues from the patients with PD after VEGF-TKI treatment had higher PD-1-positive TIIC scores at the tumor nest compared with tumors from those with PR or SD (P = 0.045) (Fig. 3F) . A more clear correlation was observed between clinical benefit and PD-1 TIIC score at the tumor periphery (P < 0.002) (Fig. 3G) . The PD-L1-positive TIIC scores at both the tumor nest and tumor periphery were also associated with clinical effects, and the difference in the mean PD-L1-positive TIIC score at the tumor periphery was greater than that at tumor nest (P = 0.016 vs P < 0.001) (Fig. 3H,I ). There was no significant correlation between clinical effects and PD-L1 tumor score (P = 0.934) (Fig. 3J ).
| Expression of PD-1 and PD-L1 in ccRCC tissues treated with VEGF-TKIs
Histologically, focal degeneration and necrosis were sporadically observed in primary ccRCC tissues treated with VEGF-TKIs, but viable tumor cells survived in all tumor tissues examined in this study. All primary ccRCC tissues treated with VEGF-TKIs (7 sorafenib-treated and 18 sunitinib-treated tumors) had PD-1-positive TIIC both at the tumor nest and tumor periphery (Fig. 4A-C) , and there were many PD-1-positive TIIC in the primary ccRCC tissues treated with VEGF-TKIs (Fig. 4B,C, arrows ). There were PD-L1-positive TIIC in 18 of 25 VEGF-TKI-treated ccRCC tissues both at the tumor nest and tumor periphery (72%) (Fig. 4E,F, arrows) , and PD-L1-positive tumor cells were observed in 10 of 25 VEGF-TKI-treated tumors (40%) (Fig. 4D-F) . The PD-L1-positive tumor cells were sporadically observed in ccRCC tissues (Fig. 4E, arrowheads) .
The PD-1-positive TIIC scores at the tumor nest and tumor periphery were significantly higher in ccRCC tissues pretreated with VEGF-TKIs (sorafenib or sunitinib) than in untreated tumors (P < 0.001 and P < 0.001, respectively) (Fig. 5A,B) . The cut-off points for the PD-1-positive TIIC score at the tumor nest for progression-free survival and overall survival were 1 and 9, and those at the tumor periphery were 2 and 2, respectively. The cut-off points for the PD-L1-positive TIIC score at the tumor nest for progression-free and overall survival were 1 and 2, and those at the tumor periphery were 1 and 3, respectively. The cut-off points for the PD-L1 tumor score were 1 and 2, respectively P < 0.001, respectively) . (Fig. 5C,D) . In contrast, there was no significant association between PD-L1 tumor score and VEGF-TKI treatment (Fig. 5E ).
| D ISCUSS I ON
In the present study, we found that both PD-1 and PD-L1 were pre- However, an elevated number of TIIC was associated with poor prognosis, 25, 26 probably because increased T cell infiltration within ccRCC tissues is often impaired and incapable of mediating tumor rejection. 27 These findings suggest that ccRCC possesses a local mechanism to undermine antitumor immunity. In the current study, we In conclusion, PD-1 and PD-L1 expression on TIIC were closely related to poor prognosis of ccRCC patients, and PD-1 and PD-L1
were also overexpressed on VEGF-TKI-treated ccRCC tissues. These findings revealed that PD-1 and PD-L1 expression on TIIC is potential antitumor biomarkers of sequential therapy by their inhibition after VEGF-TKI therapy.
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